Quell Therapeutics is pioneering the development of innovative therapies targeting severe immune-mediated diseases by harnessing the unique capabilities of regulatory T cells (Tregs). These cells play a crucial role in maintaining immune balance by suppressing pathogenic immune responses and promoting self-tolerance. Quell's approach involves engineering a patient's own Tregs to restore this balance, potentially transforming the treatment landscape for conditions such as organ transplantation, autoimmune diseases, and chronic inflammation. Their lead product, QEL-001, aims to induce operational tolerance in liver transplant recipients, thereby eliminating the need for lifelong immunosuppressive medications, which are associated with significant health risks.

The company is also expanding its Treg therapy applications beyond transplantation, with products in development for type 1 diabetes and inflammatory bowel disease. QEL-002 focuses on halting the inflammatory response in early-onset type 1 diabetes, while QEL-003 aims to reset the immune response in patients with inflammatory bowel disease who are unresponsive to existing treatments. Quell's platform includes advanced manufacturing processes and modular engineering tools designed to enhance the stability and efficacy of Treg therapies, with a vision to create off-the-shelf solutions that are more accessible and cost-effective for patients.

United Kingdom

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.

Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

Quell Therapeutics

Company Details